Skip to main content
Clinical Trials/NCT04175093
NCT04175093
Unknown
Not Applicable

A Study on Some Biomarkers in Bronchial Asthma in Children

Assiut University0 sites105 target enrollmentNovember 29, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchial Asthma
Sponsor
Assiut University
Enrollment
105
Primary Endpoint
The percentage of asymmetric dimethylarginine in the study groups
Last Updated
6 years ago

Overview

Brief Summary

Asthma, a disease characterized by chronic airway inflammation and hyper -responsiveness, is a common disease that affects all age groups. Asthma may be manifested as irreversible airflow obstruction in some patients. Although the pathogenesis of asthma is not well understood, increased oxidative stress due to an imbalance of oxidants and antioxidants has been found to be associated with asthma. In asthma, inflammation-related oxidative stress is driven by exposure to a variety of triggers, including allergens and viruses, which activate components of both the innate and acquired immune responses. Protection by escaping from triggering factors or standardization of asthma medication is difficult and usually is not enough for effective treatment. On the other hand, correction of antioxidative systems may be more efficacious in the control of asthmatic inflammation and asthma symptoms.

Little is known about the role of asymmetric dimethylarginine in the pathogenesis of asthmatic airway inflammation. The lung is a major source of asymmetric dimethylarginine that can promote oxidative stress by a reduction in nitric oxide synthesis which would result in higher levels of peroxynitrite, that causes oxidative cell damage, and exacerbate airway inflammation. asymmetric dimethylarginine can modify lung function, increase airway hyper-reactivity even in non-inflamed airways, and promote lung collagen production and deposition. Increased asymmetric dimethylarginine in serum has been found to be associated with the severity of symptoms of asthma in obese adults.

Malondialdehyde is an oxidant marker of pulmonary oxidative stress, and lipid peroxidation. Paraoxonase, an antioxidant enzyme may play a protective role in asthma. It hydrolyzes lipid peroxides and prevents low-density lipoprotein oxidation.

Registry
clinicaltrials.gov
Start Date
November 29, 2019
End Date
November 21, 2021
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sara Safwat Abd-Elaleem Hafez

Principal investigator

Assiut University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The percentage of asymmetric dimethylarginine in the study groups

Time Frame: 24 hours

measurement from serum samples by competitive ELISA with a standard range from 0.1 to 5.0 μmol/L.

Similar Trials